Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Caribou Biosciences (CRBU) over the last 4 years, with Dec 2024 value amounting to -$1.65.

  • Caribou Biosciences' EPS (Weighted Average and Diluted) rose 21.05% to -$0.30 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.70, marking a year-over-year decrease of 2.41%. This contributed to the annual value of -$1.65 for FY2024, which is 19.57% down from last year.
  • Per Caribou Biosciences' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.65 for FY2024, which was down 19.57% from -$1.38 recorded in FY2023.
  • Caribou Biosciences' 5-year EPS (Weighted Average and Diluted) high stood at -$1.38 for FY2023, and its period low was -$2.11 during FY2021.
  • For the 3-year period, Caribou Biosciences' EPS (Weighted Average and Diluted) averaged around -$1.56, with its median value being -$1.64 (2022).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first increased by 22.27% in 2022, then declined by 19.57% in 2024.
  • Yearly analysis of 4 years shows Caribou Biosciences' EPS (Weighted Average and Diluted) stood at -$2.11 in 2021, then rose by 22.27% to -$1.64 in 2022, then rose by 15.85% to -$1.38 in 2023, then declined by 19.57% to -$1.65 in 2024.